discoveri
novel
human
coronaviru
hcov
caus
newli
recogn
sever
acut
respiratori
syndrom
sar
provid
new
challeng
medic
commun
keep
control
diseas
although
human
coronavirus
caus
cold
rare
caus
lower
respiratori
tract
diseas
never
devast
effect
seen
contrast
anim
coronavirus
known
caus
devast
epizoot
respiratori
enter
diseas
livestock
fact
coronavirus
isol
avian
porcin
felin
murin
bovin
canin
known
coronavirus
categor
three
serolog
welldefin
unrel
group
sar
coronaviru
clearli
new
human
popul
rna
genom
differ
substanti
sequenc
known
natur
host
sarscov
like
civet
cat
whose
viru
acquir
abil
infect
human
interestingli
sarscov
readili
isol
grown
monkey
kidney
vero
cell
vaccin
avail
anim
coronavirus
howev
although
vaccin
live
attenu
viru
effect
porcin
epidem
diarrhoea
viru
avian
infecti
bronchiti
viru
recombin
genom
vaccin
strain
wildtyp
coronaviru
potenti
risk
appli
moreov
vaccin
felin
coronavirus
proven
enhanc
diseas
vaccin
anim
expos
wildtyp
viru
thu
antibodi
enhanc
diseas
potenti
risk
sarscov
vaccin
therefor
prudent
develop
safe
effect
drug
sarscov
quickli
possibl
case
novel
widespread
outbreak
would
occur
develop
effect
drug
sarscov
may
also
provid
new
strategi
prevent
treatment
coronaviru
diseas
anim
human
inde
approv
drug
proven
efficaci
coronavirus
ribavirin
given
sar
patient
efficaci
unclear
sever
compound
recent
mention
potenti
drug
lead
studi
evalu
varieti
compound
belong
class
pyridin
noxid
deriv
figur
sarscov
type
ii
strain
felin
infecti
periton
viru
fipv
fipv
viru
caus
sever
diseas
cat
character
vascul
dissemin
pyogranulomat
lesion
variou
tissu
organ
pyridin
noxid
compound
previous
demonstr
inhibitori
human
immunodefici
viru
hiv
cell
sever
pyridin
noxid
deriv
demonstr
act
postintegr
event
replic
cycl
hiv
ie
hiv
gene
prolong
exposur
one
prototyp
compound
scid
mice
demonstr
lack
acut
toxic
moreov
preliminari
efficaci
experi
show
protect
activ
hivinduc
destruct
human
tlymphocyt
scid
aim
present
studi
reveal
whether
pyridin
noxid
deriv
endow
inhibitori
activ
sarscov
fipv
whether
antivir
potenc
pyridin
noxid
deriv
previous
report
hiv
could
correl
antivir
activ
sarscov
fipv
structur
compound
report
sarscov
strain
kindli
provid
prof
dr
h
f
rabenau
johann
wolfgang
goeth
univers
frankfurt
germani
vero
cell
propag
minim
essenti
medium
mem
gibco
life
technolog
rockvil
md
usa
supplement
fetal
calf
serum
fc
integro
zaandam
netherland
mm
lglutamin
gibco
sodium
bicarbon
gibco
life
technolog
rockvil
md
usa
virusinfect
cell
maintain
atmospher
mem
supplement
fc
fecov
fipv
strain
origin
isol
mckeirnan
et
propag
crandel
felin
kidney
crfk
cell
maintain
medium
gibco
supplement
fetal
bovin
serum
harlan
seralab
ltd
loughborough
uk
mm
lglutamin
gibco
sodium
bicarbon
gibco
virusinfect
cell
maintain
medium
supplement
fc
antivir
activ
cytotox
measur
base
viabil
vero
cell
infect
mockinfect
cell
cultur
infect
dose
sarscov
crfk
cell
infect
mockinfect
fipv
presenc
variou
concentr
test
compound
mixtur
remov
adsorpt
phase
viru
infect
compound
present
throughout
whole
time
period
experi
three
day
sarscov
four
day
fecov
infect
number
viabl
cell
quantifi
tetrazoliumbas
colorimetr
method
previous
describ
hiv
pauwel
et
medium
aspir
replac
solut
mtt
pm
phenazinemethosulph
accord
manufactur
instruct
promega
corpor
madison
wi
usa
result
given
mean
least
independ
experi
cytotox
concentr
determin
concentr
compound
reduc
cell
viabil
cytotox
concentr
antivir
effect
concentr
determin
compound
concentr
prevent
viral
cytopath
effect
control
valu
effect
concentr
thu
valu
calcul
absorb
valu
obtain
deduct
absorb
valu
control
cultur
absorb
valu
virusinfect
cultur
reveal
stage
infect
cycl
compound
inhibitori
timeofaddit
toa
experi
carri
crfk
cell
cultur
infect
high
dose
fipv
pyridin
noxid
use
mgl
differ
time
point
postinfect
ie
h
drug
ad
infect
cell
cultur
h
full
cytopath
activ
notic
control
cultur
optic
read
mttexpos
cell
cultur
perform
quantifi
protect
effect
test
compound
ad
differ
time
point
virusinduc
cytopath
varieti
substitut
pyridin
noxid
deriv
evalu
sulphon
sulphoxid
thio
ether
link
unsubstitut
pyridin
noxid
group
phenyl
moieti
tabl
anticoronaviru
activ
rang
mgl
fipv
mgl
sarscov
depend
natur
locat
substitu
phenyl
moieti
rule
antivir
activ
record
antifipv
activ
alway
pronounc
antisarscov
activ
compound
weakli
inhibitori
fipv
show
detect
antivir
activ
sarscov
gener
sulphid
sulphoxid
deriv
show
poor
antivir
activ
coronavirus
except
inhibitori
fecov
mgl
sarscov
mgl
posit
one
alkyl
alkoxi
group
phenyl
moieti
play
mark
role
eventu
anticoronaviru
potenc
test
compound
compar
compound
gener
also
observ
halogen
nitro
cyanosubstitut
compound
potent
antivir
activ
note
trichloro
pentachloro
methyltetrachloro
nitro
deriv
mgl
fecov
mgl
sarscov
virtual
complet
lack
cytotox
activ
crfk
vero
cell
cultur
mic
mgl
compound
found
markedli
activ
mgl
fipv
activ
sarscov
subtox
concentr
instead
compound
activ
sarscov
fecov
found
seri
compound
made
contain
substitut
z
posit
link
phenyl
group
part
molecul
tabl
sever
alkylhalogenosubstitut
compound
markedli
inhibitori
sarscov
mgl
measur
activ
fipv
ie
howev
notic
compound
prove
markedli
cytotox
crfk
vero
cell
cultur
therefor
potenti
antifipv
activ
may
mask
cellular
toxic
altern
observ
antisarscov
activ
interpret
toxic
rather
specif
antivir
effect
antivir
activ
alreadi
note
unsubstitut
seri
compound
discuss
activ
pronounc
antisarscov
activ
compound
repres
except
antisarscov
activ
notic
mgl
without
trace
antifipv
activ
intriguingli
compound
toxic
crfk
cell
mgl
vero
cell
mgl
deriv
markedli
activ
fipv
sarscov
dihalogensubstitut
pyridin
noxid
deriv
effect
sarscov
fipv
tabl
also
show
antivir
activ
sarscov
fipv
intriguingli
activ
compound
seri
pyridin
noxid
deriv
contain
exclus
sulphid
moieti
wherea
sulphon
entir
devoid
antivir
activ
opposit
trend
activ
respect
sulphon
versu
sulphid
sulphoxid
previous
found
first
second
seri
compound
depict
tabl
among
pyridin
noxid
deriv
contain
alkyl
alkoxi
halogen
nitro
substitu
pyridin
moieti
addit
substitu
phenyl
bridg
pyridin
thioether
phenyl
compound
endow
pronounc
antifipv
select
tabl
inde
mgl
fipv
inact
sarscov
compound
cytotox
mgl
therefor
repres
select
antifipv
compound
among
pyridin
noxid
deriv
test
locat
chloro
substitu
pyridin
moieti
seem
crucial
sinc
move
chloro
posit
result
complet
inact
compound
besid
also
regard
highli
select
antifecov
compound
observ
none
compound
inhibitori
sarscov
fecov
compound
interest
compound
compar
potent
activ
sarscov
fipv
mgl
poorli
cytotox
mgl
crfk
mgl
vero
cell
cultur
moder
cytotox
mgl
crfk
mgl
vero
cell
cultur
tabl
total
compound
lack
oxygen
natom
pyridin
moieti
evalu
antivir
activ
tabl
rule
lack
oxid
moieti
prove
detriment
antisarscov
antifipv
activ
inde
virtual
none
test
compound
antivir
activ
subtox
concentr
fipv
sarscov
sarscov
show
antivir
activ
although
rather
close
pyridin
noxid
deriv
repres
uniqu
class
antivir
sever
member
previous
found
activ
andor
human
cytomegaloviru
hcmv
sever
dna
virus
includ
herp
simplex
viru
type
type
varicellazost
viru
vaccinia
viru
rna
virus
includ
vesicular
stomat
viru
polio
viru
coxsacki
viru
semliki
forest
viru
parainfluenza
surprisingli
pyridin
noxid
also
found
inhibitori
coronavirus
particular
felin
coronaviru
type
ii
strain
fipv
sar
coronaviru
strain
antivir
select
spectrum
rather
unusu
interestingli
previous
note
hcmv
close
correl
antivir
activ
pyridin
noxid
one
hand
fipv
sarscov
hand
r
respect
compar
antivir
activ
test
compound
found
coronavirus
given
tabl
also
correl
fipv
sarscov
cell
cultur
r
inde
number
compound
prove
exclus
inhibitori
fipv
sarscov
among
activ
compound
discrimin
fipv
sarscov
show
also
activ
pyridin
noxid
deriv
peculiar
mechan
antivir
action
previous
shown
pyridin
noxid
deriv
act
step
replic
cycl
follow
provir
integr
ie
hiv
gene
express
respect
pyridin
noxid
deriv
inhibit
bind
nuclear
dna
intact
cell
system
regener
thu
target
cellular
protein
transactiv
process
like
explan
antihivhcmv
activ
pyridin
noxid
deriv
molecular
target
anticoronaviru
activ
still
unclear
coronavirus
replic
cytoplasm
nucleu
howev
toa
experi
pyridin
noxid
deriv
ad
differ
time
point
fecov
infect
crfk
cell
cultur
reveal
addit
compound
virusinfect
cell
could
substanti
delay
lose
antivir
potenti
figur
similar
toa
experi
hiv
human
lymphocyt
cem
cell
cultur
reveal
also
postintegr
event
target
replic
cycl
thu
compound
inhibit
viru
replic
event
clearli
locat
viral
entri
act
like
transcript
process
viru
replic
cycl
howev
differ
antivir
activ
also
cytotox
depend
viru
type
hiv
fecov
sarscov
cell
type
cem
crfk
vero
indic
rather
specif
interact
cellular
andor
viral
factor
explain
rather
unpredict
antivir
cytostat
properti
pyridin
noxid
deriv
respect
oxid
form
compound
seem
crucial
maintain
anticoronaviru
activ
requir
much
less
stringent
keep
activ
compar
antihiv
anticoronaviru
activ
reduc
pyridin
noxid
tabl
despit
pronounc
cytostat
activ
notic
prolifer
human
cem
lymphocyt
cell
cultur
pyridin
noxid
deriv
often
poorli
cytotox
confluent
crfk
vero
cell
cultur
result
pronounc
select
indic
sever
compound
exceed
two
order
magnitud
moreov
compound
repres
one
inhibitori
select
anticoronaviru
compound
studi
lack
pronounc
select
cem
cell
cultur
administ
mice
mgkgday
day
upon
continu
releas
alzet
pump
mgkgday
intraperiton
consecut
day
experiment
condit
result
visibl
sign
toxic
side
effect
drugexpos
anim
observ
may
justifi
indepth
studi
pharmacokinet
relat
compound
potenti
pyridin
noxid
deriv
anticoronaviru
drug
vivo
conclus
select
anticoronaviru
activ
found
sever
pyridin
noxid
deriv
cell
cultur
may
warrant
preclin
investig
reveal
potenti
class
antivir
drug
select
inhibitor
coronavirus
includ
sarscov
infect
human
fecov
infect
cat
author
financi
conflict
interest
regard
content
investig
